BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 13, 2026
Home » Topics » Briefs

Briefs
Briefs RSS Feed RSS

In the clinic for April 21, 2023

April 21, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Beigene, Bioinvent, Cantex, Dare, Maia, Promore, Sellas, Visus.
Read More

Financings for April 21, 2023

April 21, 2023
Biopharmas raising money in public or private financings, including: Cyclo, Pharmaessentia, Phio, Sirona.
Read More

Appointments and advancements for April 21, 2023

April 21, 2023
New hires and promotions in the biopharma industry, including: Allogene, Immvira, Lianbio.
Read More

Regulatory actions for April 20, 2023

April 20, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: GE Healthcare, Meridian Bioscience, Noctrix Health.
Read More

Other news to note for April 20, 2023

April 20, 2023
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott Laboratories, Cercare Medical, Concertai, Element Biosciences, Epic Sciences, Gemina, Grail, Illumina, Mdxhealth, Nvidia, Radimagenet, Readygo, Science 37, Segmed, Surmodics
Read More

In the clinic for April 20, 2023

April 20, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bend Health, Grail, Icecure Medical, Vialase.
Read More

Appointments and advancements for April 20, 2023

April 20, 2023
New hires and promotions in the med-tech industry, including: Anaconda Biomed, Semler Scientific, Nevro.
Read More

Regulatory actions for April 20, 2023

April 20, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cel-Sci, CSL, Nascent, SAB, Taiho, Zucara.
Read More

Other news to note for April 20, 2023

April 20, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amgen, Astellas, Blue Water, LG Chem, Moderna, Novartis, Sandoz, Senisca, Twist, Veru, Zydus.
Read More

In the clinic for April 20, 2023

April 20, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annovis, Cali, Ideaya, Leyden, Longeveron, Myrtelle, Nykode,  Palleon, Revolo, Plus.
Read More
Previous 1 2 … 820 821 822 823 824 825 826 827 828 … 1808 1809 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • Blood sample tubes after centrifuge

    Pre-disease plasma signature may help redefine lung cancer risk

    BioWorld
    Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
  • New 5-HT2C receptor agonists reported in Hansoh patent

    BioWorld Science
    Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
  • Virtual IPO word with stock graph and arrow

    Parabilis takes top spot, pricing largest biopharma IPO at $670M

    BioWorld
    Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing